ERIS Lifesciences Ltd

ERIS Lifesciences Ltd | Sector: Pharmaceuticals | ISIN: INE406M01024

₹ 570.65 (0.37%) icon

24 Mar, 2023, 3:29:55 PM
Open
₹ 568.95
Prev. Close
₹ 568.55
Turnover(lac)
₹ 960.43
Day's High
₹ 576.30
Day's Low
₹ 555.00
52 Wk High
₹ 749.80
52 Wk Low
₹ 551.30
Book Value
₹ 163.85
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 7,760.40
P/E
19.62
EPS
29.18
Div. Yield
1.05

Stock View

info icon
Edit Image

STRONG BUY

Target | 20 Mar, 2023

805.4 (40.58%)

Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in G... Read More

KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 3/24/2023 3:29:55 PM

    ₹ 570.65 2.10 0.37
  • Open
  • ₹ 568.95
  • Prev. Close
  • ₹ 568.55
  • Turnover(Lac.)
  • ₹ 960
  • Day's High
  • ₹ 576.3
  • Day's Low
  • ₹ 555
  • 52 Week's High
  • ₹ 749.8
  • 52 Week's Low
  • ₹ 551.3
  • Book Value
  • ₹ 163.85
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 7,760.4
  • P/E
  • 19.62
  • EPS
  • 29.18
  • Divi. Yield
  • 1.05

Corporate Actions

10 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 Jan , 2023

12:00 AM

11 Oct , 2022

12:00 AM

11 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

15 Jun , 2022

12:00 AM

AGM

Announcement date: 15 Jun , 2022

View Details

05 Aug , 2022

12:00 AM

Dividend

Dividend amount: 7.35
Announcement date: 05 Aug , 2022

View Details

29 Jul , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jul , 2022

12:00 AM

15 Jun , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Apr , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Apr , 2022

12:00 AM

05 Aug , 2022

12:00 AM

BookCloser

View Details

SHAREHOLDING SNAPSHOT
27 March , 2023 | 06:23 AM

PROMOTER - TOTAL52.70%

Indian: 52.70%

Foreign: 0%

NON-PROMOTER - TOTAL 47.30%

Institutions: 25.44%

Non-Institutions: 21.85%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

ERIS Lifesciences Ltd News and Update

Image not found
  • 24 March, 2023 |
  • 4:03 PM

According to a BSE filing, the parties to the proposed transaction, for which a legally binding memorandum of understanding had previously been signed, had "executed a Share Purchase Agreement and finalized the transaction."

Article Image
Article Image
  • IIFL News Service |
  • 23 March, 2023 |
  • 4:02 PM
ad IconAd Image

FINANCIALS

PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT ERIS Lifesciences Ltd

  • Amit Indubhushan Bakshi

  • Chairman & Managing Director
  • Inderjeet Singh Negi

  • Whole-time Director
  • Milind Talegaonkar

  • Company Sec. & Compli. Officer
  • Prashant Gupta

  • Independent Director
  • Kaushal Shah

  • Executive Director
  • Krishnakumar Vaidyanathan

  • Executive Director & COO
  • Rajeev Narotam Dalal

  • Independent Director
  • Kalpana Unadkat

  • Independent Director
  • Sujesh Vasudevan

  • Addtnl Independent Director

Summary

Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to Eris Lifesciences Private Limited on February 9, 2007. Further, the company was converted into a public limited company and the name was changed to Eris Lifesciences Limited on February 2, 2017. The Company has a manufacturing plant located in Guwahati, Assam and is presently engaged in the manufacturing, distributing and marketing of branded pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists.In 2007, the company launched Eris division focused on cardiology and diabetes segment. In 2008, the company launched Nikkos division focused on gastroenterology and orthopedics segment. In 2009, the company launched Adura division... Read More


Reports by ERIS Lifesciences Ltd


Reports by ERIS Lifesciences Ltd